Evaluation of in vitro antimicrobial combined effects on carbapenem-resistant Enterobacterales and carbapenemase-producing Enterobacterales

Abstract

The spread of carbapenem-resistant Enterobacterales(CRE) and the high mortality rate of CRE infections are serious problems in the antimicrobial therapy. CRE is a multidrug-resistant that has acquired resistance to various antibacterial, and its resistance genes and antibacterial susceptibility are regional. Antibacterial combination therapy is used to treat CRE infections, but there are concerns about adverse reactions to colistin (CL) and tigecycline (TGC), which are expected to be effective. In recent years, new antibacterial that are effective against CRE have been developed, but it will take some time before they are approved in Japan. For the time being, CRE infections will have to treat by existing antibacterial, and the challenge is how to enhance the ineffective ones to make them effective. Therefore, considering combination therapies that do not use CL and TGC is important for establishing treatment guidelines for future CRE infections.